Safety of Terbogrel in Patients With Primary Pulmonary Hypertension

Summary

Study to assess the safety of terbogrel during open-label, long-term treatment in medically stable or improving patients with primary pulmonary hypertension who have completed the 12-week, double-blind randomized trial of terbogrel (protocol 528.19)

Timeline

Start

1998-10

Primary completion

2000-03

Completion

—

Drugs

Indications